We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

34 hedge funds and large institutions have $15.7M invested in VistaGen Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

767% more capital invested

Capital invested by funds: $1.82M → $15.7M (+$13.9M)

494% more call options, than puts

Call options by funds: $4.96M | Put options by funds: $835K

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

19.74% more ownership

Funds ownership: 12.35% → 32.09% (+20%)

3% more funds holding

Funds holding: 33 → 34 (+1)

8% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 12

Holders
34
Holders Change
+1
Holders Change %
+3.03%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
7
Closed
12
Calls
$4.96M
Puts
$835K
Net Calls
+$4.13M
Net Calls Change
+$4.09M

Top Buyers

1
CC
Commodore Capital
New York
+$6.99M
2
IC
Ikarian Capital
Texas
+$1.02M
3
SSA
Schonfeld Strategic Advisors
New York
+$615K
4
BCM
BML Capital Management
Indiana
+$444K
5
SFM
Sphera Funds Management
Israel
+$444K

Top Sellers

1
GCP
GSA Capital Partners
United Kingdom
-$675K
2
Millennium Management
Millennium Management
New York
-$374K
3
Goldman Sachs
Goldman Sachs
New York
-$107K
4
YIH
Y-Intercept (HK)
Hong Kong
-$89.2K
5
CSS
Cubist Systematic Strategies
Connecticut
-$77.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Commodore Capital
New York
$8.25M +$6.99M +1,575,000 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.33M +$132K +29,804 +13%
IC
3
Ikarian Capital
Texas
$1.2M +$1.02M +229,100 New
SSA
4
Schonfeld Strategic Advisors
New York
$726K +$615K +138,500 New
BCM
5
BML Capital Management
Indiana
$524K +$444K +100,000 New
SFM
6
Sphera Funds Management
Israel
$524K +$444K +100,000 New
BlackRock
7
BlackRock
New York
$461K -$75.3K -16,960 -16%
William Blair & Company
8
William Blair & Company
Illinois
$446K +$378K +85,173 New
Group One Trading
9
Group One Trading
Illinois
$395K +$324K +72,913 +3,048%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$384K +$70.3K +15,842 +28%
MA
11
MYDA Advisors
New York
$262K +$222K +50,000 New
BFM
12
Boothbay Fund Management
New York
$246K +$208K +46,895 New
GCP
13
GSA Capital Partners
United Kingdom
$245K -$675K -152,034 -76%
State Street
14
State Street
Massachusetts
$133K – – –
PCM
15
Prelude Capital Management
New York
$106K +$89.7K +20,200 New
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$101K +$31.3K +7,053 +57%
Millennium Management
17
Millennium Management
New York
$88.4K -$374K -84,200 -83%
Northern Trust
18
Northern Trust
Illinois
$76.1K +$18.5K +4,171 +40%
RJA
19
Raymond James & Associates
Florida
$52.4K +$44.4K +10,000 New
Citadel Advisors
20
Citadel Advisors
Florida
$44.8K -$50.3K -11,319 -57%
GWSG
21
GPS Wealth Strategies Group
Colorado
$44.2K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$25.2K +$16.3K +3,668 +320%
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$15K +$12K +2,711 +1,819%
Morgan Stanley
24
Morgan Stanley
New York
$13.4K -$3.82K -860 -25%
Carson Wealth (CWM LLC)
25
Carson Wealth (CWM LLC)
Nebraska
$13K -$5.92K -1,333 -35%
1
2

VTGN Hedge Fund Activity: Q3 2023 in Review

34 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2023, worth a combined $15.7M — up 767% from $1.82M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new VTGN positions and 12 closed out — a net gain of 1 holder — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Commodore Capital, opening a new position worth an estimated $6.99M. The largest seller was GSA Capital Partners, cutting an estimated $675K.

  • 34 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2023, up from 33 in Q2 2023.
  • Funds reported $15.7M of VistaGen Therapeutics stock for Q3 2023, up 767% quarter-over-quarter.
  • 13 funds opened new VistaGen Therapeutics positions in Q3 2023 and 12 closed out, a net change of +1 holder.
  • The largest VistaGen Therapeutics buyer in Q3 2023 was Commodore Capital, an estimated $6.99M added.
  • The largest VistaGen Therapeutics seller in Q3 2023 was GSA Capital Partners, an estimated $675K sold.

Based on aggregated 13F filings for Q3 2023.